Vistin Pharma — Earnings Release 2021

Apr 23, 2021

Vistin Pharma ASA: First quarter 2021 financial results

Vistin Pharma ASA: First quarter 2021 financial results

Oslo, Norway, 23(rd) of April 2021

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial

results for the first quarter 2021

Vistin Pharma delivers another strong quarter with 15% increase in revenue YoY.

Q1'21 revenue ended at MNOK 70.8 (Q1'20: MNOK 61.4).

First quarter EBITDA for pharmaceuticals was MNOK 16.3 (Q1'20: MNOK 14.2) a 15%

increase compared to similar quarter last year

The net profit for the group ended at MNOK 8.8 (Q1'20: negative MNOK 168) for

the first quarter of 2021. The net loss in Q1'20 was driven by closing of the

oil derivative contracts.

Vistin Pharma had cash of MNOK 85 (Q1'20 MNOK: 317) as of 31 March 2021. Approx.

35% of the Metformin Expansion Project (MEP) has been paid as of March. The

company has a strong balance sheet with an equity ratio of 86% and no interest-

bearing debt.

The Fikkjebakke plant has been running at full capacity an achieved an all-time

high production volume in the quarter driven by full effect of the 2nd reactor

installed in Q3/Q4'20

The first quarter conference call, which will be held today, 23rd of April, at

8.30am (CET) and will be available via web and audio through the following

access points:

Telephone conference:

Confirmation Code:........ 4598958

International Dial-In:....... +44 (0) 2071 928338

Norway, Oslo:................ +47 21563015

United States, New York: +1 6467413167

Webcast:

https://edge.media-server.com/mmc/p/rso5ngk4

The conference call will be held in Norwegian.

Please find the Q1 report and presentation enclosed. The report will also be

made available on www.vistin.com (http://www.vistin.com).

*****

For further information, please contact:

Kjell-Erik Nordby

CEO

+47 91 36 42 80

kjell-erik.nordby@vistin.com (mailto:kjell-erik.nordby@vistin.com)

Alexander Karlsen

CFO

+47 97 05 36 21

alexander.karlsen@vistin.com (mailto:alexander.karlsen@vistin.com)

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.